Table S7: Prentice-Freedman Criteria

Study Number	Treatment effect on outcomes unadjusted for change in urine protein				Treatment effect on outcomes adjusted for change in urine protein			PTE (95% CI)
	Estimate	SE	Hazard Ratio	P-value	Estimate	SE	Hazard Ratio	
A1	-0·22	0·12	0·81	0·083	-0·06	0·15	0·94	71·16 (-38·23, 180·56)
A4	-0·62	0·22	0·54	0·005	-0·44	0·23	0·64	28·63 (-3·19, 60·45)
A8	-0·71	0·32	0·49	0·028	-0·70	0·38	0·50	0·37 (-58·29, 59·03)
A10	-0·51	0·20	0·60	0·009	-0·06	0·24	0·94	87·50 (4·50, 170·50)
A12	-0·64	0·21	0·53	0·003	-0·39	0·22	0·68	38·35 (5·05, 71·66)
A13	-0·23	0·08	0·80	0·003	-0·09	0·08	0·92	62·22 (15·03, 109·41)
A14	-0·67	0·24	0·51	0·006	-0·54	0·27	0·58	19·66 (-12·29, 51·62)
A15	-0·22	0·10	0·80	0·027	-0·12	0·11	0·88	44·45 (-13·01, 101·90)
B1	-0·41	0·15	0·66	0·008	-0·23	0·17	0·80	44·87 (-11·50, 101·23)
B15	-0·33	0·10	0·72	0·001	-0·22	0·11	0·80	33·87 (-0·02, 67·76)
E21	-0·68	0·31	0·51	0·026	-1·01	0·35	0·36	-48·56 (-124·38, 27·27)
E23	-1·01	0·34	0·36	0·003	-0·61	0·34	0·54	39·62 (6·58, 72·65)
A	-0·29	0·05	0·75	0·000	-0·16	0·05	0·85	43·94 (25·25, 62·63)
B	-0·29	0·08	0·74	<0.001	-0·20	0·08	0·82	33·69 (3·59, 63·79)
C	-0·15	0·07	0·86	0·038	-0·08	0·08	0·92	46·24 (-19·61, 112·08)
D	-0·21	0·13	0·81	0·097	-0·14	0·13	0·87	30·85 (-14·31, 76·01)
E	-0·61	0·19	0·54	0·001	-0·66	0·20	0·52	-6·95 (-40·62, 26·71)

Clinical outcomes includes ESRD, doubling of serum creatinine or death. All treatment effect estimates are adjusted for baseline urine protein, irrespective of whether change in urine protein is adjusted for. Urine protein was log transformed in statistical analyses. SE, standard error; PTE, Proportion of treatment effect; CI, confidence interval.

A is RAS (renin angiotensin system) Blockade vs. control, **B** is RAS Blockade vs. CCB (calcium channel blocker), **C** is Intensive Blood Pressure **D** is Low protein diet, and **E** is Immunosuppressive therapy.

Each study is referred by an alphanumeric code. Each letter refers to treatment comparisons, and each number refers to the individual studies. **A** is RAS (renin angiotensin system) Blockade vs. Control, **B** is RAS Blockade vs. CCB (calcium channel blocker), **C** is Intensive Blood Pressure **D** is Low protein diet, and **E** is Immunosuppressive therapy. For studies with multiple interventions, there will be multiple letter-number codes for that study. For example, AASK which had multiple interventions: RAS Blockage vs. placebo, RAS Blockade vs. CCB, and Blood pressure control. Its study number is 1, but it has three codes to indicate the specific treatment comparison: A1, B1 and C1.